Is patient-centricity in clinical development a real commitment or just empty jargon?
Across the industry, patient-centricity has increasingly garnered attention in recent years from the media, sponsors, CROs and other pharmaceutical service and technology providers. However, the industry lacks a common approach to patient-centricity, which makes it even more elusive to determine how patient-centric clinical development really is. Are sponsors and contract research organizations truly focused on patients and taking their preferences and needs into account? If so, how? If not, why not?
Following a survey of our global database of clinical trial professionals, in collaboration with SCORR Marketing, this report reveals exclusive insights into the perceptions, practices and future expectations of patient-centricity in clinical trials in 2017.
CROs, pharma, service providers, academia and patient groups split across North America, Europe and Asia are all represented, creating results that provide a ‘state of the industry’ picture.
Some key statistics from the survey include:
- 77% of respondents say it is extremely or very important that their company embrace patient-centricity while another 16% consider it of moderate importance.
- Respondents consider patient-centricity to be even more important to patients themselves (87%) but far less important to their competitors (53%).
- 29% said their companies don’t solicit input from patients and 36% indicate their companies don’t measure patient-centricity from the patient’s perspective.
- When gathering input from patients, patient advocacy groups are most commonly used (48%), followed by focus groups and individual interviews (both at 42%).